SCHEMBL26501563

SCHEMBL26501563

C=C(C)c1ccc(CC(=O)N[C@H]2CCN(c3ccc(C)nn3)C2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GLS O94925 17/20 0.41
SIGMAR1 Q99720 1/20 0.40
KMT2A Q03164 1/20 0.38
PANK3 Q9H999 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31717392 0.89 PANK3 (0.50) SIGMAR1PANK3
SCHEMBL19748934 0.89 PANK3 (0.50) SIGMAR1PANK3
SCHEMBL19748933 0.89 PANK3 (0.50) SIGMAR1PANK3
SCHEMBL26501533 0.84 GLS (0.47) GLSSIGMAR1
SCHEMBL26501582 0.81 SIGMAR1 (0.41) GLSSIGMAR1PANK3
SCHEMBL26501564 0.78 SIGMAR1 (0.44) GLSSIGMAR1PANK3
SCHEMBL26501535 0.75 PANK3 (0.52) GLSSIGMAR1PANK3
SCHEMBL18890179 0.74 GLS (0.53) GLSKMT2A
SCHEMBL23750436 0.73 PANK3 (0.51) SIGMAR1PANK3
SCHEMBL31717785 0.73 PANK3 (0.51) SIGMAR1PANK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321092-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321092-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR HMGCR, GCDH, CYP11A1 GLS 57/4885SIGMAR1 3593/4885KMT2A 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.